Trials / Recruiting
RecruitingNCT06536179
New Preclinical and Clinical Approaches to Mesothelioma
New Preclinical and Clinical Approaches to Mesothelioma, an Archetypal Inflammatory Tumor
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 70 (estimated)
- Sponsor
- Marco Emilio Bianchi · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study protocol involves the coordination between UO1 (IRCCS San Raffaele Hospital) and UO2 (Istituto Nazionale Tumori di Napoli - IRCCS G. Pascale) to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis. UO1 focuses on the role of HMGB1 in inflammation, mesothelioma progression, and tissue repair, as well as developing, in future, possible HMGB1 inhibitors for cancer therapy. UO2 specializes in CXCR4's role in cancer, developing CXCR4 antagonists, and tracking CXCR4-dependent metastasis. The hypothesis is that targeting HMGB1 and CXCR4 pathways will inhibit tumor progression and metastasis, enhancing anti-tumor immunity and improving therapeutic outcomes in cancer.
Detailed description
This is a multicentric cross-sectional observational study with an additional blood volume collected during blood sampling performed for normal clinical practice. The enrollment will take
Conditions
Timeline
- Start date
- 2024-07-25
- Primary completion
- 2025-07-25
- Completion
- 2027-01-25
- First posted
- 2024-08-02
- Last updated
- 2024-08-02
Locations
2 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT06536179. Inclusion in this directory is not an endorsement.